| Literature DB >> 30140369 |
Serafina Perrone1, Antonino Santacroce1, Mariangela Longini1, Fabrizio Proietti1, Francesco Bazzini1, Giuseppe Buonocore1.
Abstract
During the perinatal period, free radicals (FRs) are involved in several physiological roles such as the cellular responses to noxia, the defense against infectious agents, the regulation of cellular signaling function, and the induction of a mitogenic response. However, the overproduction of FRs and the insufficiency of an antioxidant mechanism result in oxidative stress (OS) which represents a deleterious process and an important mediator of damage to the placenta and the developing fetus. After birth, OS can be magnified by other predisposing conditions such as hypoxia, hyperoxia, ischemia, hypoxia ischemia-reperfusion, inflammation, and high levels of nonprotein-bound iron. Newborns are particularly susceptible to OS and oxidative damage due to the increased generation of FRs and the lack of adequate antioxidant protection. This impairment of the oxidative balance has been thought to be the common factor of the so-called "free radical related diseases of prematurity," including retinopathy of prematurity, bronchopulmonary dysplasia, intraventricular hemorrhage, periventricular leukomalacia, necrotizing enterocolitis, kidney damage, and oxidative hemolysis. In this review, we provide an update focused on the factors influencing these diseases refining the knowledge about the role of OS in their pathogenesis and the current evidences of such relationship. Mechanisms governing FR formation and subsequent OS may represent targets for counteracting tissue damage.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30140369 PMCID: PMC6081521 DOI: 10.1155/2018/7483062
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1Cellular sources of free radicals (a); antioxidant protection within the cell (b).
Figure 2Schematic representation of vascular cerebral injury.
Antioxidants and diseases: clinical trials.
| Disease | Antioxidant | Outcome | References |
|---|---|---|---|
| BPD | Lutein | Possible positive association between lutein and respiratory health | Melo van Lent, Leermakers; 2016 |
| iNO + vitamin A | Reduced the incidence of BPD and BPD + death and improved neurocognitive outcomes at 1 year in the 500–749 g birth weight group | Gadhia, Cutter; 2014 | |
| Recombinant human SOD | Reduced early pulmonary injury, resulting in improved clinical status at 1 year corrected age | Davis, Parad; 2003 | |
| Melatonin | Newborns who developed BPD had levels of IL-6, IL-8, TNF-alpha, and nitrite/nitrate values much higher than those in children who did not develop BPD | Gitto et al.; Pineal Res; 2004 | |
| Vitamin A | Vitamin A supplementation does not reduce the incidence of BPD | Gawronski CA, Gawronski KM, Ann Pharmacother; 2016 | |
|
| |||
| NEC | L-Arginine | Enteral L-arginine supplementation appears to reduce the incidence of stage III NEC in VLBW infant | Polycarpou et al., 2013 |
| Pentoxifylline | Pentoxifylline did not change the risk of development of NEC in neonates with sepsis | Pammi et al., 2015 | |
| Melatonin | Melatonin administration as an adjuvant therapy in neonatal NEC treatment is associated with improvement of clinical and laboratory outcome | [ | |
|
| |||
| ROP | Vitamin A | A trend towards reduced incidence of retinopathy of prematurity in vitamin A-supplemented infants | Darlow et al., Cochrane Database Syst Rev; 2002 |
| Vitamin E | There was a 52% reduction in the incidence of stage 3+ ROP in VLBW infants | [ | |
| D-Penicillamine | Six of the 70 surviving control infants and none of the 71 surviving treated infants had ROP stage II or greater Prophylactic enterally administered DPA does not prevent any stage ROP | Lakatos et al., Acta Paediatr; 1986 | |
| Recombinant human SOD | rhSOD reduces the risk of developing ROP in extremely low gestational age newborn | Parad et al., Neonatology; 2012 | |
| Lutein | There were no differences in the incidence of ROP at any stage between groups | Romagnoli et al., J Matern Fetal Neonatal Med.; 2011 | |
| Allopurinol | Failure of allopurinol prophylaxis to prevent ROP | Russel et al., Arch Dis Child Fetal Neonatal Ed; 1995 | |
Figure 3Schematic representation of oxidative red blood cell injury.